National Cardiogenic Shock Initiative: 1 Year Later

Video Chapters:The Impact of The Cardiogenic Shock Initiative (NCSI):...

Dr. Michael Amponsah Cardiogenic Shock Case with Impella CP

Dr. Michael Amponsah of Central New York Cardiology/Mohawk Valley Health System shares a case of Impella CP for a non-ischemic...

The Door-to-Unloading (DTU) STEMI Safety & Feasibility Trial

Navin Kapur, MD, executive director of the CardioVascular Center for Research and Innovation at Tufts Medical Center, discusses...

Best Practice Protocols for Cardiogenic Shock Showing Improved Outcomes Within the WellStar System

Dr. Salvatore Mannino, Director of the Short-Term Mechanical Circulatory Support Program at WellStar Health System joins Dr. Se...

Identification of Complications and Early Management

Dr. Adhir Shroff of the University of Illinois at Chicago recently presented at the SCAI Fellows 2017 conference during a works...

Heart Team Approach to Treating Cardiogenic Shock

Dr. Alexander Truesdell of INOVA Heart and Vascular Institute compares his experience in combat medicine and combat medical car...

Q&A: Weaning Off of Impella

When do you being weaning off the Impella device for Protected PCI and Cardiogenic Shock patients? Learn from Drs. Tony DeMarti...

Q&A: Impella RP® Heart Pump

How has the Impella RP improved your practice? Hear from Dr. Mark Goodwin of Edward-Elmhurst Hospital. Related C...

Q&A: Implanting Impella During Cardiogenic Shock Cases

How do you manage your staff to ensure the physician on call is able to place the Impella device during cardiogenic shock cases...

Q&A: Mean Arterial Pressure

How do you use mean arterial pressure vs. other hemodynamic metrics? Hear from Dr. Tim Larkin of Edward-Elmhurst Health....

How to Better Evaluate, Identify and Manage Shock Patients

Recently, Abiomed’s platform of Impella® heart pumps received FDA approval for the treatment of patients experiencing cardio...

The FDA’s Shock Indication for the Impella

The FDA recently granted Abiomed approval to expand Impella™ 2.5 PMA to treat patients suffering cardiogenic shock follo...